Compatible with the results of our study and as mentioned before, CpGs type A (e.g. ODN 2116) show only little B-cell activation [18], which is reflected by the relative low TNF-α and MIP-1α production of CpGs type A treated CLL cells. Here, CCL3 is linked to B-cell chronic lymphocytic leukemia.